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To the Editor: In their article, Oza et al. proposed a 
score to risk-stratify Ebola virus disease (EVD) suspected 
cases while patients in an Ebola treatment center await 
laboratory confirmation (1). The Ebola symptom-based 
risk (ESR) score, consisting of 6 symptoms (conjunctivitis, 
diarrhea, nausea/vomiting, headache, difficulty breathing, 
loss of appetite), performed well in internal validation, but 
no external validation was done.
 We evaluated the proposed ESR score on 805 
EVD-positive and 1,506 EVD-negative case-patients 
in the Conakry Ebola Treatment Center (ETC), Cona-
kry, Guinea (2). The ESR score yielded an area under 
the curve of 0.58 (95% CI 0.56–0.61), which is lower 
than the 0.83 (95% CI 0.79–0.86) Oza et al. reported 
(online Technical Appendix Figure, https://wwwnc.cdc.
gov/EID/article/24/6/17-1812-Techapp1.pdf). Using the 
proposed risk thresholds (i.e., low risk if score <0, me-
dium risk if score = 0, and high risk if score >0), 371 
(46%) EVD-positive patients of the Conakry ETC were 
classified as high risk and 647 (43%) EVD-negative 
patients as low risk. However, negative and positive 
predictive values were generally low (online Technical 
Appendix Table). Reasons for poor validation could in-
clude differences in applying the general EVD suspect 
case definition (integration of patients’ contact history); 
in patient characteristics because organization and access 
to care for EVD and non-EVD illness was different (pa-
tients in holding centers or ETC); in the quality of data 
collection (symptoms are entirely self-reported); and in 
underlying diseases of EVD-negative patients. 
Our findings underline the importance of external vali-
dation in various settings before risk scores are applied out-
side of the setting within which they were developed, as 
well as the need to incorporate patient contact history into 
predictive models. Point-of-care EVD diagnostic platforms 
can perform reliable confirmatory testing within 90 min-
utes (3). We argue that, by integrating rapid confirmatory 
testing in triage, providers can avoid classifying patients by 
their likelihood of infection with Ebola virus while waiting 
for laboratory confirmation. 
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